These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 33527058)

  • 1. Persistent Immune Thrombocytopenia Resistant to Immunosuppressive Therapy: What Is the Way Forward?
    Kamarul Bahrin MH; Vijayenthiran H; Stimson L; Ahmad H
    Cureus; 2020 Dec; 12(12):e12377. PubMed ID: 33527058
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Severe romiplostim-induced rebound thrombocytopenia after splenectomy for refractory ITP.
    Choe MJ; Packer CD
    Ann Pharmacother; 2015 Jan; 49(1):140-4. PubMed ID: 25325908
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Successful treatment of refractory secondary immune thrombocytopenia (antiphospholipid antibody syndrome-associated) with the combination of rituximab and romiplostim at the cost of severe bone pain: A case report and review of literature.
    Yassa G; Shakir AR; Jagarlamudi K; Yassa AE
    J Oncol Pharm Pract; 2021 Jan; 27(1):253-257. PubMed ID: 32611269
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of romiplostim in a hemodialysis patient with primary immune thrombocytopenia.
    Al-Jafar H; Giagounidis A; El-Rashaid K; Al-Ali M; Hakim AA
    Ann Pharmacother; 2012 Nov; 46(11):e31. PubMed ID: 23115229
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pathogenesis of chronic immune thrombocytopenia: increased platelet destruction and/or decreased platelet production.
    Nugent D; McMillan R; Nichol JL; Slichter SJ
    Br J Haematol; 2009 Sep; 146(6):585-96. PubMed ID: 19466980
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Romiplostim in chronic immune thrombocytopenic purpura.
    Cersosimo RJ
    Clin Ther; 2009 Sep; 31(9):1887-907. PubMed ID: 19843480
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune thrombocytopenic purpura presenting in a patient after renal transplant for diabetic nephropathy.
    Rashid RM; Nabi Z; Ansari AZ; Qaiser QA
    BMC Nephrol; 2018 Mar; 19(1):69. PubMed ID: 29554892
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of romiplostim in splenectomized and nonsplenectomized patients with immune thrombocytopenia.
    Perdomo J
    Immunotargets Ther; 2016; 5():1-7. PubMed ID: 27529057
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Recent progress in immune thrombocytopenia pathophysiology and treatment].
    Kato H
    Rinsho Ketsueki; 2023; 64(9):1106-1115. PubMed ID: 37899189
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Diagnostic approach and treatment of immune thrombocytopenia in adults].
    Kolonić SO; Patekar MB; Milunović V
    Acta Med Croatica; 2013 Mar; 67(1):3-11. PubMed ID: 24279250
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Persistent Relapsing Immune Thrombocytopenia Following COVID-19 Infection.
    Boehm BA; Packer CD
    Cureus; 2022 Jul; 14(7):e27133. PubMed ID: 36004011
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Delayed treatment-free response after romiplostim discontinuation in pediatric chronic immune thrombocytopenia.
    Lim HJ; Lim YT; Hah JO; Lee JM
    Yeungnam Univ J Med; 2021 Apr; 38(2):165-168. PubMed ID: 32891076
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Dilemma, Bernard Soulier Syndrome
    J B; Patel NK; Kumar N; Singh J; Kumar K
    Cardiovasc Hematol Disord Drug Targets; 2023; 23(1):72-75. PubMed ID: 37114784
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Platelet destruction in immune thrombocytopenia. Understanding the mechanisms.
    Bakchoul T; Sachs UJ
    Hamostaseologie; 2016 Aug; 36(3):187-94. PubMed ID: 25982994
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Review of Romiplostim Mechanism of Action and Clinical Applicability.
    Bussel JB; Soff G; Balduzzi A; Cooper N; Lawrence T; Semple JW
    Drug Des Devel Ther; 2021; 15():2243-2268. PubMed ID: 34079225
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Romiplostim: a breakthrough treatment for the management of immune thrombocytopenic purpura.
    Newland A
    Eur J Haematol Suppl; 2009 Mar; (71):20-5. PubMed ID: 19200304
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The treatment for primary immune thrombocytopenia with romiplostim in adult and paediatric patients: use experience at a Spanish university hospital.
    Marquínez-Alonso I; Escudero-Vilaplana V; Pernía S; Beléndez Bieler C; Fernández-Llamazares CM; Sanjurjo-Sáez M
    J Clin Pharm Ther; 2014 Aug; 39(4):376-82. PubMed ID: 24702274
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Idiopathic thrombocytopenic purpura in children].
    Gebauer E; Vijatov G
    Med Pregl; 1998; 51(3-4):127-34. PubMed ID: 9611955
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pneumococcal 13-Valent Conjugate Vaccine (Prevnar 13)-Associated Immune Thrombocytopenic Purpura in a Renal Transplant Recipient: A Case Report.
    Gupta S; Brennan DC
    Transplant Proc; 2016; 48(1):262-4. PubMed ID: 26915880
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thrombopoietin receptor agonist (TPO-RA) treatment raises platelet counts and reduces anti-platelet antibody levels in mice with immune thrombocytopenia (ITP).
    Kapur R; Aslam R; Speck ER; Rebetz JM; Semple JW
    Platelets; 2020; 31(3):399-402. PubMed ID: 31146647
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.